Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pharmaceutical Clinical Educators: A Resource for Advanced Practice Providers.

Arrington SA, Farrell LA, Henning J.

J Adv Pract Oncol. 2018 Jan-Feb;9(1):86-89. Epub 2018 Jan 1. Review.

2.

Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.

Elmariah S, Farrell LA, Furman D, Lindman BR, Shi X, Morningstar JE, Rhee EP, Gerszten RE.

JAMA Cardiol. 2018 Mar 1;3(3):242-246. doi: 10.1001/jamacardio.2017.4873.

3.

Genetic Architecture of the Cardiovascular Risk Proteome.

Benson MD, Yang Q, Ngo D, Zhu Y, Shen D, Farrell LA, Sinha S, Keyes MJ, Vasan RS, Larson MG, Smith JG, Wang TJ, Gerszten RE.

Circulation. 2018 Mar 13;137(11):1158-1172. doi: 10.1161/CIRCULATIONAHA.117.029536. Epub 2017 Dec 19.

4.

Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.

Jacob J, Ngo D, Finkel N, Pitts R, Gleim S, Benson MD, Keyes MJ, Farrell LA, Morgan T, Jennings LL, Gerszten RE.

Circulation. 2018 Mar 20;137(12):1270-1277. doi: 10.1161/CIRCULATIONAHA.117.029443. Epub 2017 Dec 8.

5.

Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O'Sullivan JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, Carr SA, Wang TJ, Gerszten RE.

Circulation. 2016 Jul 26;134(4):270-85. doi: 10.1161/CIRCULATIONAHA.116.021803.

6.

Metabolite Profiles Predict Acute Kidney Injury and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement.

Elmariah S, Farrell LA, Daher M, Shi X, Keyes MJ, Cain CH, Pomerantsev E, Vlahakes GJ, Inglessis I, Passeri JJ, Palacios IF, Fox CS, Rhee EP, Gerszten RE.

J Am Heart Assoc. 2016 Mar 15;5(3):e002712. doi: 10.1161/JAHA.115.002712.

7.

Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study.

Maron BA, Stephens TE, Farrell LA, Oldham WM, Loscalzo J, Leopold JA, Lewis GD.

J Heart Lung Transplant. 2016 Mar;35(3):342-351. doi: 10.1016/j.healun.2015.10.019. Epub 2015 Oct 19.

8.

Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.

Keshishian H, Burgess MW, Gillette MA, Mertins P, Clauser KR, Mani DR, Kuhn EW, Farrell LA, Gerszten RE, Carr SA.

Mol Cell Proteomics. 2015 Sep;14(9):2375-93. doi: 10.1074/mcp.M114.046813. Epub 2015 Feb 27.

9.

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA.

Nat Biotechnol. 2011 Jun 19;29(7):635-43. doi: 10.1038/nbt.1899.

10.

Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease.

Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH.

Neuroscience. 2007 Jun 29;147(2):354-72. Epub 2007 Jun 4.

11.

Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.

Sadri-Vakili G, Menon AS, Farrell LA, Keller-McGandy CE, Cantuti-Castelvetri I, Standaert DG, Augood SJ, Yohrling GJ, Cha JH.

Eur J Neurosci. 2006 Jun;23(12):3171-5.

PMID:
16820007
12.

Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.

Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH.

Neurobiol Dis. 2006 May;22(2):233-41. Epub 2006 Jan 24.

PMID:
16442295
13.

Neurotransmitter receptor analysis in transgenic mouse models.

Benn CL, Farrell LA, Cha JH.

Methods Mol Biol. 2004;277:231-60.

PMID:
15201460
14.

Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.

Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH.

Neurobiol Dis. 2003 Dec;14(3):624-36.

PMID:
14678777
15.

Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation.

Yohrling GJ, Farrell LA, Hollenberg AN, Cha JH.

Mol Cell Neurosci. 2003 May;23(1):28-38.

PMID:
12799135
16.

Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein.

Cha JH, Farrell LA, Ahmed SF, Frey A, Hsiao-Ashe KK, Young AB, Penney JB, Locascio JJ, Hyman BT, Irizarry MC.

Neurobiol Dis. 2001 Feb;8(1):90-102.

PMID:
11162243
17.

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM.

Nat Med. 2000 Jul;6(7):797-801.

PMID:
10888929

Supplemental Content

Loading ...
Support Center